MedPath
EMA Product

Duaklir Genuair

Product approved by European Medicines Agency (EU)

Basic Information

Duaklir Genuair

Regulatory Information

EMEA/H/C/003745

Authorised

November 19, 2014

September 25, 2014

16

February 26, 2025

Company Information

the netherlands

Gustav Mahlerplein 2 1082 MA Amsterdam

Covis Pharma Europe BV

Active Substances Detail

aclidinium bromideformoterol fumarate dihydrate

Detailed Information

Therapeutic Indication

### Therapeutic indication Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Overview Summary

This is a summary of the European public assessment report (EPAR) for Duaklir Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duaklir Genuair. For practical information about using Duaklir Genuair, patients should read the package leaflet or contact their doctor or pharmacist.

© Copyright 2025. All Rights Reserved by MedPath